{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,27]],"date-time":"2026-09-27T05:38:42Z","timestamp":1790487522597,"version":"4.1.0"},"reference-count":17,"publisher":"Japanese Society for Lymphoreticular Tissue Research","issue":"3","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["JCEH","J Clin Exp Hematopathol"],"published-print":{"date-parts":[[2025]]},"DOI":"10.3960\/jslrt.25017","type":"journal-article","created":{"date-parts":[[2025,8,27]],"date-time":"2025-08-27T22:07:53Z","timestamp":1756332473000},"page":"180-184","source":"Crossref","is-referenced-by-count":1,"title":["Bridging therapy with valemetostat to allogeneic hematopoietic cell transplantation for adult T-cell leukemia\/lymphoma"],"prefix":"10.3960","volume":"65","author":[{"given":"Shota","family":"Furukawa","sequence":"first","affiliation":[{"name":"Department of Hematopoietic Stem Cell Transplantation, National Cancer Center Hospital, Tokyo, Japan,"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ayumu","family":"Ito","sequence":"additional","affiliation":[{"name":"Department of Hematopoietic Stem Cell Transplantation, National Cancer Center Hospital, Tokyo, Japan,"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Koji","family":"Jimbo","sequence":"additional","affiliation":[{"name":"Department of Hematology\/Oncology, Research Hospital, The Institute of Medical Science, The University of Tokyo, Japan,"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Masataka","family":"Sakashita","sequence":"additional","affiliation":[{"name":"Department of Hematology\/Oncology, Research Hospital, The Institute of Medical Science, The University of Tokyo, Japan,"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sakiko","family":"Harada","sequence":"additional","affiliation":[{"name":"Department of Hematology, Juntendo University Nerima Hospital, Tokyo, Japan,"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mamoru","family":"Nagata","sequence":"additional","affiliation":[{"name":"Department of Hematopoietic Stem Cell Transplantation, National Cancer Center Hospital, Tokyo, Japan,"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Takayuki","family":"Fujii","sequence":"additional","affiliation":[{"name":"Department of Hematopoietic Stem Cell Transplantation, National Cancer Center Hospital, Tokyo, Japan,"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Asako","family":"Usui","sequence":"additional","affiliation":[{"name":"Department of Hematopoietic Stem Cell Transplantation, National Cancer Center Hospital, Tokyo, Japan,"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mizuki","family":"Watanabe","sequence":"additional","affiliation":[{"name":"Department of Hematopoietic Stem Cell Transplantation, National Cancer Center Hospital, Tokyo, Japan,"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wataru","family":"Takeda","sequence":"additional","affiliation":[{"name":"Department of Hematopoietic Stem Cell Transplantation, National Cancer Center Hospital, Tokyo, Japan,"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tsuneaki","family":"Hirakawa","sequence":"additional","affiliation":[{"name":"Department of Hematopoietic Stem Cell Transplantation, National Cancer Center Hospital, Tokyo, Japan,"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kazuaki","family":"Yokoyama","sequence":"additional","affiliation":[{"name":"Department of Hematology\/Oncology, Research Hospital, The Institute of Medical Science, The University of Tokyo, Japan,"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aki","family":"Sato","sequence":"additional","affiliation":[{"name":"Department of Hematology\/Oncology, Research Hospital, The Institute of Medical Science, The University of Tokyo, Japan,"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Makoto","family":"Yamagishi","sequence":"additional","affiliation":[{"name":"Laboratory of Tumor Cell Biology, Department of Computational Biology and Medical Sciences, Graduate School of Frontier Sciences, The University of Tokyo, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kaoru","family":"Uchimaru","sequence":"additional","affiliation":[{"name":"Department of Hematopoietic Stem Cell Transplantation, National Cancer Center Hospital, Tokyo, Japan,"},{"name":"Laboratory of Tumor Cell Biology, Department of Computational Biology and Medical Sciences, Graduate School of Frontier Sciences, The University of Tokyo, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yasuhito","family":"Nannya","sequence":"additional","affiliation":[{"name":"Department of Hematology\/Oncology, Research Hospital, The Institute of Medical Science, The University of Tokyo, Japan,"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Takahiro","family":"Fukuda","sequence":"additional","affiliation":[{"name":"Department of Hematopoietic Stem Cell Transplantation, National Cancer Center Hospital, Tokyo, Japan,"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"2349","reference":[{"key":"1","doi-asserted-by":"crossref","unstructured":"1 Alaggio R, Amador C, Anagnostopoulos I, <i>et al.<\/i> The 5th edition of the World Health Organization Classification of Haematolymphoid Tumours: Lymphoid Neoplasms. Leukemia. 2022; 36: 1720-1748.","DOI":"10.1038\/s41375-022-01620-2"},{"key":"2","doi-asserted-by":"crossref","unstructured":"2 Gessain A, Cassar O. Epidemiological aspects and world distribution of HTLV-1 infection. Front Microbiol. 2012; 3: 388.","DOI":"10.3389\/fmicb.2012.00388"},{"key":"3","doi-asserted-by":"crossref","unstructured":"3 Ito S, Iwanaga M, Nosaka K <i>et al.<\/i> Epidemiology of adult T-cell leukemia-lymphoma in Japan: An updated analysis, 2012-2013. Cancer Sci. 2021; 112: 4346-4354.","DOI":"10.1111\/cas.15097"},{"key":"4","doi-asserted-by":"crossref","unstructured":"4 Shimoyama M. Diagnostic criteria and classification of clinical subtypes of adult T-cell leukaemia-lymphoma. A report from the Lymphoma Study Group (1984-87). Br J Haematol. 1991; 79: 428-437.","DOI":"10.1111\/j.1365-2141.1991.tb08051.x"},{"key":"5","doi-asserted-by":"crossref","unstructured":"5 Imaizumi Y, Iwanaga M, Nosaka K <i>et al.<\/i> Prognosis of patients with adult T-cell leukemia\/lymphoma in Japan: A nationwide hospital-based study. Cancer Sci. 2020; 111: 4567-4580.","DOI":"10.1111\/cas.14658"},{"key":"6","doi-asserted-by":"crossref","unstructured":"6 Fukushima T, Nomura S, Shimoyama M <i>et al.<\/i> Japan Clinical Oncology Group (JCOG) prognostic index and characterization of long-term survivors of aggressive adult T-cell leukaemia-lymphoma (JCOG0902A). Br J Haematol. 2014; 166: 739-748.","DOI":"10.1111\/bjh.12962"},{"key":"7","doi-asserted-by":"crossref","unstructured":"7 Tsukasaki K, Fukushima T. JSH Practical Guidelines for Hematological Malignancies, 2018: II. Lymphoma-8. Adult T-cell leukemia-lymphoma. Int J Hematol. 2019; 109: 249-259.","DOI":"10.1007\/s12185-018-02588-5"},{"key":"8","doi-asserted-by":"crossref","unstructured":"8 Fujiwara H, Fuji S, Wake A <i>et al.<\/i> Dismal outcome of allogeneic hematopoietic stem cell transplantation for relapsed adult T-cell leukemia\/lymphoma, a Japanese nation-wide study. Bone Marrow Transplant. 2017; 52: 484-488.","DOI":"10.1038\/bmt.2016.313"},{"key":"9","doi-asserted-by":"crossref","unstructured":"9 Fuji S, Inoue Y, Utsunomiya A <i>et al.<\/i> Pretransplantation anti-CCR4 antibody mogamulizumab against adult T-cell leukemia\/lymphoma is associated with significantly increased risks of severe and corticosteroid-refractory graft-versus-host disease, nonrelapse mortality, and overall mortality. J Clin Oncol. 2016; 34: 3426-3433.","DOI":"10.1200\/JCO.2016.67.8250"},{"key":"10","doi-asserted-by":"crossref","unstructured":"10 Yamagishi M, Hori M, Fujikawa D <i>et al.<\/i> Targeting excessive EZH1 and EZH2 activities for abnormal histone methylation and transcription network in malignant lymphomas. Cell Rep. 2019; 29: 2321-2337.e7.","DOI":"10.1016\/j.celrep.2019.10.083"},{"key":"11","doi-asserted-by":"crossref","unstructured":"11 Fujikawa D, Nakagawa S, Hori M <i>et al.<\/i> Polycomb-dependent epigenetic landscape in adult T-cell leukemia. Blood. 2016; 127: 1790-1802.","DOI":"10.1182\/blood-2015-08-662593"},{"key":"12","doi-asserted-by":"crossref","unstructured":"12 Yamagishi M, Kuze Y, Kobayashi S <i>et al.<\/i> Mechanisms of action and resistance in histone methylation-targeted therapy. Nature. 2024; 627: 221-228.","DOI":"10.1038\/s41586-024-07103-x"},{"key":"13","doi-asserted-by":"crossref","unstructured":"13 Izutsu K, Makita S, Nosaka K <i>et al.<\/i> An open-label, single-arm phase 2 trial of\u00a0valemetostat\u00a0for relapsed or refractory adult T-cell\u00a0leukemia\/lymphoma. Blood. 2023; 141: 1159-1168.","DOI":"10.1182\/blood.2022016862"},{"key":"14","doi-asserted-by":"crossref","unstructured":"14 Maruyama D, Jacobsen E, Porcu P <i>et al.<\/i> Valemetostat monotherapy in patients with relapsed or refractory non-Hodgkin lymphoma: a first-in-human, multicentre, open-label, single-arm, phase 1 study. Lancet Oncol. 2024; 25: 1589-1601.","DOI":"10.1016\/S1470-2045(24)00502-3"},{"key":"15","doi-asserted-by":"crossref","unstructured":"15 Zinzani PL, Izutsu K, Mehta-Shah N <i>et al.<\/i> Valemetostat for patients with relapsed or refractory peripheral T-cell lymphoma (VALENTINE-PTCL01): a multicentre, open-label, single-arm, phase 2 study. Lancet Oncol. 2024; 25: 1602-1613.","DOI":"10.1016\/S1470-2045(24)00503-5"},{"key":"16","doi-asserted-by":"crossref","unstructured":"16 Kobayashi S, Nakano K, Watanabe E <i>et al.<\/i> CADM1 expression and stepwise downregulation of CD7 are closely associated with clonal expansion of HTLV-I-infected cells in adult T-cell leukemia\/lymphoma. Clin Cancer Res. 2014; 20: 2851-2861.","DOI":"10.1158\/1078-0432.CCR-13-3169"},{"key":"17","doi-asserted-by":"crossref","unstructured":"17 Bagnato G, Stefoni V, Broccoli A <i>et al.<\/i> Successful bridging to allogeneic transplantation with valemetostat in two refractory\/relapsed peripheral T-cell lymphoma patients. Mediterr J Hematol Infect Dis. 2024; 16: e2024004.","DOI":"10.4084\/MJHID.2024.004"}],"container-title":["Journal of Clinical and Experimental Hematopathology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.jstage.jst.go.jp\/article\/jslrt\/65\/3\/65_25017\/_pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,4]],"date-time":"2025-10-04T04:43:48Z","timestamp":1759553028000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.jstage.jst.go.jp\/article\/jslrt\/65\/3\/65_25017\/_article"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025]]},"references-count":17,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2025]]}},"URL":"https:\/\/doi.org\/10.3960\/jslrt.25017","relation":{},"ISSN":["1346-4280","1880-9952"],"issn-type":[{"value":"1346-4280","type":"print"},{"value":"1880-9952","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025]]},"article-number":"25017"}}